USA News Group News
Commentary
Issued on behalf of Oncolytics Biotech
Inc.
VANCOUVER, BC, May 24, 2024
/PRNewswire/ -- USA News
Group News Commentary – As the 2024 American Society of
Clinical Oncology (ASCO) annual meeting approaches, excitement
builds over the latest in cancer treatment advancements,
particularly in Antibody-Drug Conjugates (ADCs). From May 31 to June 4, industry leaders will unveil
new data on late-stage and approved therapies. Recent FDA
approvals are also enriching the treatment landscape, offering
patients innovative and improved cancer therapies. This pivotal
event highlights the ongoing momentum in oncology research and
treatment development, spotlighted by several developments recently
announced by biotech companies, including: Oncolytics
Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Merk & Co.,
Inc. (NYSE: MRK), Roche Holding AG (OTCQX: RHHBY),
Amgen Inc. (NASDAQ: AMGN), and BioNTech SE (NASDAQ:
BNTX).
The article continued: According to the National Cancer
Institute, there will be an estimated 2,001,140 new cases of
cancer diagnosed in the USA in
2024, with an expected 611,720 people projected to die from the
disease. Throughout 2023, the FDA granted a total of 50
approvals for various oncology drugs.
Oncolytics Biotech® ASCO Abstracts Highlight
Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic
Mechanism of Action
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a
leading clinical-stage company specializing in immunotherapy for
oncology, today announced it has presented two abstracts
at the 2024 American Society of Clinical Oncology (ASCO)
Annual Meeting. One is a trial-in-progress abstract discussing
cohort 5 of the GOBLET study, which will evaluate the combination
of pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with and
without atezolizumab in newly diagnosed metastatic pancreatic
ductal adenocarcinoma (PDAC) patients. The second describes
pelareorep's ability to induce the expansion of tumor-infiltrating
lymphocytes (TILs) across multiple cancers and the correlation
between TIL expansion and tumor response.
"The two abstracts that we are sharing at ASCO this year are in
synch with our mission of advancing pelareorep towards
registrational trials. The first abstract outlines the design of a
new GOBLET PDAC cohort that could significantly expand the
potential of the company's pancreatic cancer program," said Dr.
Matt Coffey, President and Chief
Executive Officer of Oncolytics. "The chemotherapy regimens
of mFOLFIRINOX and gemcitabine/nab-paclitaxel are the two most
common standards of care in metastatic pancreatic cancer. We
previously reported that the combination of pelareorep,
gemcitabine, nab-paclitaxel, and atezolizumab yielded tumor
response rates nearly triple historical results. Should the
combination of pelareorep and mFOLFIRINOX produce a similarly
positive outcome, an even broader range of metastatic PDAC patients
may benefit from pelareorep-based therapy. This cohort is being
funded by a US$5 million grant in the
form of the Therapeutic Accelerator Award from the Pancreatic
Cancer Action Network (PanCAN). We anticipate enrollment in
this cohort will begin this quarter."
Thomas Heineman, MD, PhD, Chief
Medical Officer of Oncolytics stated, "Pelareorep stimulates
a proinflammatory response that primes tumors for immunologic
killing and also activates both innate and adaptive immune
responses. Our second ASCO abstract provides additional support for
pelareorep's immunotherapeutic mechanism of action by describing
its ability to stimulate the expansion of pre-existing and new TIL
clones in the blood, which correlate with treatment response. These
results build upon previously reported data from the AWARE-1 study
in breast cancer to expand our understanding of pelareorep's
immune-based mechanism of action, and it supports further
investigation of TIL expansion as a potential biomarker of clinical
activity in patients treated with pelareorep."
At the ASCO 2024 meeting, Oncolytics will present
findings from its research on pelareorep in metastatic pancreatic
ductal adenocarcinoma. This research is part of a Phase 1/2
randomized, multicenter study in which one cohort evaluates
pelareorep combined with modified FOLFIRINOX with and without
atezolizumab. Initially, the study will include 15 patients in each
treatment group, focusing on the treatment's safety and
effectiveness, with plans to expand if initial success criteria are
met. Additionally, another presentation at ASCO will explore how
pelareorep enhances tumor-infiltrating lymphocytes (TILs) in the
blood in patients with pancreatic, breast, and colon cancer,
showing promising signs that TIL expansion correlates with better
treatment responses. A copy of the PDAC poster presentation will be
available on Oncolytics' website after the meeting concludes
and the abstracts are available on the ASCO website, providing
valuable insights into pelareorep's potential to improve outcomes
in various cancers.
CONTINUED… Read this and more news for Avant Technologies
at: https://equity-insider.com/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
In other industry developments and happenings in the market
this week include:
Merk & Co., Inc. (NYSE: MRK), a global healthcare
company that develops, manufactures, and markets a wide range of
pharmaceuticals, vaccines, and animal health products, recently
announced it will also present new data at the 2024 ASCO
Annual Meeting, demonstrating advancements in novel oncology
treatment approaches across their broad portfolio and diverse
pipeline. The new data comes from four approved oncology medicines
and four pipeline candidates in more than 25 types of cancer.
"At ASCO, the breadth of data across multiple types of
cancer and stages of disease underscores our efforts to drive
innovations that have potential to shape the future of oncology,"
said Dr. Marjorie Green, Senior Vice
President and Head of Oncology, Global Clinical Development,
Merck Research Laboratories. "This year's ASCO is
also particularly meaningful as we approach 10 years since KEYTRUDA
was first approved in the U.S. Reflecting back, it is remarkable to
see just how much the oncology treatment landscape has transformed,
thanks to the significant contributions from patients, researchers
and physicians around the world."
Roche Holding AG (OTCQX: RHHBY), through its leading
wholly-owned biotechnology subsidiary Genentech, recently
announced that the FDA has granted Breakthrough Therapy
Designation to its proprietary inavolisib for advanced hormone
receptor-positive, HER2-negative breast cancer with a PICK3CA
mutation. Breakthrough Therapy Designation expedites the
development and review of drugs meant to treat serious or
life-threatening conditions, especially when initial clinical
evidence suggests they may offer significant improvements over
existing treatments.
"We are pleased that the FDA granted Breakthrough Therapy
Designation for inavolisib in recognition of the substantial
clinical benefit observed with this regimen," said Levi Garraway, M.D., Ph.D., Genentech's
chief medical officer and head of Global Product Development. "This
promising inavolisib-based regimen could transform the PI3K
inhibitor class, potentially becoming the standard of care for this
patient population in the first-line setting."
Amgen Inc. (NASDAQ: AMGN), a biotech company that
develops innovative therapeutics in areas including oncology,
nephrology, and cardiology, announced that the FDA has
approved its asset IMDELLTRA™ as the first and only T-cell engager
therapy for the treatment of extensive-stage small cell lung
cancer. IMDELLTRA has received accelerated approval based on
positive results observed in clinical studies, including the
response rate and duration of response. The continued approval for
this treatment may depend on further confirmation and detailed
outcomes from additional clinical trials.
"The FDA's approval of IMDELLTRA marks a pivotal moment for
patients battling ES-SCLC. This DLL3-targeting therapy in ES-SCLC
comprises a transformative option demonstrating long-lasting
responses in pretreated patients," said Jay
Bradner, M.D., executive vice president, Research and
Development, and chief scientific officer at Amgen. "This
approval further demonstrates our commitment to addressing
aggressive cancers through our second FDA-approved Bispecific
T-cell Engager (BiTE®) molecule. IMDELLTRA offers these
patients who are in urgent need of new innovative therapies hope,
and we're proud to deliver this long-awaited effective treatment to
them."
BioNTech SE (NASDAQ: BNTX), a global next-generation
immunotherapy company pioneering novel therapies for cancer and
other serious diseases, announced it will present clinical
trial data for selected programs from the company's diversified
immuno-oncology pipeline at ASCO 2024. BioNTech will
present epidemiological and real-world data from two observational
studies in patient populations for which product candidates are
being developed in its respective clinical programs.
"Our aim is to develop innovative treatment options across the
continuum of cancer disease and establish new treatment paradigms
that have the potential to address the fundamental challenges of
treating cancer to drive meaningful improvements in the long-term
survival rates for patients," said Prof. Özlem Türeci, M.D.,
Co-Founder and Chief Medical Officer at BioNTech. "The data
from the interventional and observational studies that we will
present at this year's ASCO are of relevance for progress towards
our goal as they will contribute to informing the direction of
further development of several of our priority product candidates
as well as the design of planned pivotal and later-stage clinical
trials across all three key pillars of our diversified oncology
pipeline, including novel immunomodulators, targeted therapies such
as cell therapies and ADCs, and mRNA-based therapeutic cancer
vaccines."
Source:
https://equity-insider.com/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
CONTACT:
USA NEWS
GROUP
info@usanewsgroup.com
(604)
265-2873
DISCLAIMER: Nothing in this publication should be
considered as personalized financial advice. We are not licensed
under securities laws to address your particular financial
situation. No communication by our employees to you should be
deemed as personalized financial advice. Please consult a licensed
financial advisor before making any investment decision. This is a
paid advertisement and is neither an offer nor recommendation to
buy or sell any security. We hold no investment licenses and are
thus neither licensed nor qualified to provide investment advice.
The content in this report or email is not provided to any
individual with a view toward their individual circumstances.
USA News Group is a wholly-owned
subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been
paid a fee for Oncolytics Biotech Inc. advertising and digital
media from the company directly. There may be 3rd parties who may
have shares of Oncolytics Biotech Inc., and may liquidate their
shares which could have a negative effect on the price of the
stock. This compensation constitutes a conflict of interest as to
our ability to remain objective in our communication regarding the
profiled company. Because of this conflict, individuals are
strongly encouraged to not use this publication as the basis for
any investment decision. The owner/operator of MIQ own shares of
Oncolytics Biotech Inc. which were purchased in the open market,
and reserve the right to buy and sell, and will buy and sell shares
of Oncolytics Biotech Inc. at any time without any further notice
commencing immediately and ongoing. We also expect further
compensation as an ongoing digital media effort to increase
visibility for the company, no further notice will be given, but
let this disclaimer serve as notice that all material, including
this article, which is disseminated by MIQ has been approved by
Oncolytics Biotech Inc.; this is a paid advertisement, we currently
own shares of Oncolytics Biotech Inc. and will buy and sell shares
of the company in the open market, or through private placements,
and/or other investment vehicles.
While all information is believed to be reliable, it is not
guaranteed by us to be accurate. Individuals should assume that all
information contained in our newsletter is not trustworthy unless
verified by their own independent research. Also, because events
and circumstances frequently do not occur as expected, there will
likely be differences between the any predictions and actual
results. Always consult a licensed investment professional before
making any investment decision. Be extremely careful, investing in
securities carries a high degree of risk; you may likely lose some
or all of the investment.
View original
content:https://www.prnewswire.com/news-releases/emerging-trends-in-oncology-asco-2024-highlights-next-gen-antibody-drug-conjugates-and-more-302155293.html
SOURCE USA News Group